189 related articles for article (PubMed ID: 37186134)
1. Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.
Hu A; Chen G; Bao B; Guo Y; Li D; Wang X; Wang J; Li Q; Zhou Y; Gao H; Song J; Du X; Zheng L; Tong Q
Clin Transl Med; 2023 Apr; 13(4):e1235. PubMed ID: 37186134
[TBL] [Abstract][Full Text] [Related]
2. p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation.
Yang F; Hu A; Guo Y; Wang J; Li D; Wang X; Jin S; Yuan B; Cai S; Zhou Y; Li Q; Chen G; Gao H; Zheng L; Tong Q
Mol Cancer; 2021 Sep; 20(1):123. PubMed ID: 34579723
[TBL] [Abstract][Full Text] [Related]
3. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
4. SMARCC2 combined with c‑Myc inhibits the migration and invasion of glioma cells via modulation of the Wnt/β‑catenin signaling pathway.
Li C; Fei C; Li J; Wu H; Chen L; Roshani R; Li H; Shi L; Song C; Gu J; Lu Y; Zhou Q
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080022
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma.
Yamamoto T; Kohashi K; Yamada Y; Kawata J; Sakihama K; Matsuda R; Koga Y; Aishima S; Nakamura M; Oda Y
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2945-2957. PubMed ID: 34817661
[TBL] [Abstract][Full Text] [Related]
6. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
8. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
9. Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency.
Agaimy A; Cheng L; Egevad L; Feyerabend B; Hes O; Keck B; Pizzolitto S; Sioletic S; Wullich B; Hartmann A
Am J Surg Pathol; 2017 Feb; 41(2):253-262. PubMed ID: 27984237
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.
Fang E; Wang X; Wang J; Hu A; Song H; Yang F; Li D; Xiao W; Chen Y; Guo Y; Liu Y; Li H; Huang K; Zheng L; Tong Q
Theranostics; 2020; 10(4):1555-1571. PubMed ID: 32042322
[TBL] [Abstract][Full Text] [Related]
11. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression.
Song H; Li D; Wang X; Fang E; Yang F; Hu A; Wang J; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
J Hematol Oncol; 2020 Mar; 13(1):24. PubMed ID: 32216806
[TBL] [Abstract][Full Text] [Related]
12. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
13. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF Alterations in Squamous Bladder Cancers.
Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
[TBL] [Abstract][Full Text] [Related]
15. ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT.
Bui CB; Le HK; Vu DM; Truong KD; Nguyen NM; Ho MAN; Truong DQ
Mol Carcinog; 2019 Nov; 58(11):1998-2007. PubMed ID: 31365169
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.
Zhang Z; Li Q; Sun S; Li Z; Cui ZG; Zhang M; Liu Q; Zhang Y; Xiong S; Zhang S
World J Surg Oncol; 2022 Dec; 20(1):383. PubMed ID: 36464671
[TBL] [Abstract][Full Text] [Related]
17. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
18. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
19. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
20. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
